Halozyme Signs Licensing Deal with Incyte for Subcutaneous Formulation of INCA033989

HALO Halozyme Therapeutics Inc

$102.98 +0.06%

View chart & analysis →

INCY -1.30%

1. 1Halozyme (HALO) has entered into a global collaboration and licensing agreement with Incyte (INCY).
2. 2The deal applies Halozyme's ENHANZE technology to the development of a subcutaneous formulation of Incyte's antibody INCA033989, with Halozyme to receive upfront and milestone payments plus future sales royalties, while Incyte retains the option to designate two additional targets.
3. 3The agreement adds another partner to Halozyme's technology licensing network, though the size of the upfront and milestone payments has not been disclosed.

Source InvestorsHub +1 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →